RUNX1 and acute myeloid leukemia: Further success with JQ1 was also described by Gröschel et al., where treatment with the compound led to significantly reduced EVI1 expression and growth arrest of inv(3) AML cells, but no sensitivity in cells that have no rearrangement at that locus and yet overexpress EVI1 (Gröschel et al., 2014).